Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Laquinimod in Huntington's disease
NL-OMON44575Phase 2Active, not recruiting
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- May 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of laquinimod in Huntington disease (HD), sponsored by Teva Pharmaceutical Industries Ltd.. Started May 2016; status: active, not recruiting.
02
Drugs
laquinimod
03
Conditions
Huntington disease (HD)
Beyond the preview
Go deeper on NL-OMON44575.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44575.